BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25415613)

  • 1. KCa3.1: a new player in progressive kidney disease.
    Huang C; Pollock CA; Chen XM
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):61-6. PubMed ID: 25415613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of KCa3.1 ameliorates renal fibrosis through the TGF-β1/Smad pathway in diabetic mice.
    Huang C; Shen S; Ma Q; Chen J; Gill A; Pollock CA; Chen XM
    Diabetes; 2013 Aug; 62(8):2923-34. PubMed ID: 23656889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the potassium channel KCa3.1 in diabetic nephropathy.
    Huang C; Pollock CA; Chen XM
    Clin Sci (Lond); 2014 Oct; 127(7):423-33. PubMed ID: 24963668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KCa3.1 mediates dysfunction of tubular autophagy in diabetic kidneys via PI3k/Akt/mTOR signaling pathways.
    Huang C; Lin MZ; Cheng D; Braet F; Pollock CA; Chen XM
    Sci Rep; 2016 Mar; 6():23884. PubMed ID: 27029904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High glucose induces CCL20 in proximal tubular cells via activation of the KCa3.1 channel.
    Huang C; Pollock CA; Chen XM
    PLoS One; 2014; 9(4):e95173. PubMed ID: 24733189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis.
    Huang C; Shen S; Ma Q; Gill A; Pollock CA; Chen XM
    Nephrol Dial Transplant; 2014 Feb; 29(2):313-24. PubMed ID: 24166472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy.
    Huang C; Zhang L; Shi Y; Yi H; Zhao Y; Chen J; Pollock CA; Chen XM
    PLoS One; 2018; 13(2):e0192800. PubMed ID: 29425253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy.
    Mulay SR; Gaikwad AB; Tikoo K
    Chem Biol Interact; 2010 Apr; 185(2):137-42. PubMed ID: 20223228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role and mechanism of K
    Ma XZ; Pang ZD; Wang JH; Song Z; Zhao LM; Du XJ; Deng XL
    Exp Cell Res; 2018 Aug; 369(2):208-217. PubMed ID: 29792849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted inhibition of KCa3.1 channel attenuates airway inflammation and remodeling in allergic asthma.
    Yu ZH; Xu JR; Wang YX; Xu GN; Xu ZP; Yang K; Wu DZ; Cui YY; Chen HZ
    Am J Respir Cell Mol Biol; 2013 Jun; 48(6):685-93. PubMed ID: 23492185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K
    Pang ZD; Wang Y; Wang XJ; She G; Ma XZ; Song Z; Zhao LM; Wang HF; Lai BC; Gou W; Du XJ; Deng XL
    FASEB J; 2019 Dec; 33(12):14760-14771. PubMed ID: 31690106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward.
    Blumenthal SS
    Postgrad Med; 2011 Nov; 123(6):166-79. PubMed ID: 22104465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor-β/Smad signalling in diabetic nephropathy.
    Lan HY
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):731-8. PubMed ID: 22211842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic nephropathy: where hemodynamics meets metabolism.
    Forbes JM; Fukami K; Cooper ME
    Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):69-84. PubMed ID: 17318765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy.
    Brizzi MF; Dentelli P; Rosso A; Calvi C; Gambino R; Cassader M; Salvidio G; Deferrari G; Camussi G; Pegoraro L; Pagano G; Cavallo-Perin P
    FASEB J; 2004 Aug; 18(11):1249-51. PubMed ID: 15180953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease.
    Li JH; Huang XR; Zhu HJ; Oldfield M; Cooper M; Truong LD; Johnson RJ; Lan HY
    FASEB J; 2004 Jan; 18(1):176-8. PubMed ID: 12709399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the TGF-β/BMP-7/Smad pathways in renal diseases.
    Meng XM; Chung AC; Lan HY
    Clin Sci (Lond); 2013 Feb; 124(4):243-54. PubMed ID: 23126427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
    Yamout H; Lazich I; Bakris GL
    Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KCa3.1 Ca2+ activated K+ channels regulate human airway smooth muscle proliferation.
    Shepherd MC; Duffy SM; Harris T; Cruse G; Schuliga M; Brightling CE; Neylon CB; Bradding P; Stewart AG
    Am J Respir Cell Mol Biol; 2007 Nov; 37(5):525-31. PubMed ID: 17585114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.